Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Lung Cancer

Expert Opinion / Cases · February 01, 2022

Acquired Resistance to Osimertinib in EGFR Mutant NSCLC

Written by
Michael J. Grant MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Lewis Attas

    Feb 07, 2022

    I think 5 is the best answer . i would continue osi  and add the RET inhibitor 

  • Angela Xu

    Feb 09, 2022

    I choose 5. Might add some anti angiogenesis as well. Let targeted therapies do their best and last switch to chemo.

  • Jean-Yves Douillard

    Feb 14, 2022

    I would suggest to keep Osimertinib and add Selpercatinib considering the new existence of a detectable RET fusion as an additional target for which the drug has been approved. I would rather chemotherapy as long as possible.

  • Apr 23, 2024

    Pending Moderator approval.

Further Reading